In dapagliflozin-treated patients, rs3813008 (in SLC5A2) was significantly associated with increased risk of CV mortality and HF hospitalizations (HR = 3.09, 95% CI: 1.30–7.39, P = 0.011). Here, SLC5A2 is linked to hydrops fetalis.